Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience

Salman Fazal

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Treating Adults With Newly Diagnosed ALL

MyCancerHaven

R. Vij, A. Patel

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Axatilimab in cGVHD: Mechanism of Action and Comparison With Current…

Noah Merin

The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibro…

Daniel Wolff

Considering Venetoclax in AML and ALL - Which Patients and Why

Marina Konopleva

The Truth About Current Consensus Statements on Hematopoietic Cell T…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale